See more : Amaru, Inc. (AMRU) Income Statement Analysis – Financial Results
Complete financial analysis of PAVmed Inc. (PAVM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PAVmed Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Auswide Bank Ltd (ABA.AX) Income Statement Analysis – Financial Results
- AIT Corporation (9381.T) Income Statement Analysis – Financial Results
- C3 Metals Inc. (CUAUF) Income Statement Analysis – Financial Results
- Sistema Public Joint Stock Financial Corporation (SSA.IL) Income Statement Analysis – Financial Results
- Bitcoin Depot Inc. (BTMWW) Income Statement Analysis – Financial Results
PAVmed Inc. (PAVM)
About PAVmed Inc.
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.45M | 377.00K | 500.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.42M | 3.61M | 585.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 0.00 | 0.00 |
| Gross Profit | -3.97M | -3.24M | -85.00K | -23.00K | -14.23K | -9.79K | -7.11K | -3.79K | 0.00 | 0.00 |
| Gross Profit Ratio | -161.83% | -858.62% | -17.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 14.28M | 25.55M | 19.85M | 10.96M | 6.63M | 4.25M | 2.62M | 1.72M | 489.33K | 22.29K |
| General & Administrative | 30.95M | 41.04M | 25.57M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 0.00 |
| Selling & Marketing | 17.58M | 19.32M | 8.90M | 2.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.53M | 60.36M | 34.46M | 12.39M | 7.66M | 6.31M | 5.42M | 3.93M | 1.29M | 400.00K |
| Other Expenses | 2.02M | 1.78M | 0.00 | 0.00 | -558.60K | -903.00K | -3.12M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 64.83M | 87.69M | 54.31M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Cost & Expenses | 71.25M | 91.30M | 54.89M | 23.35M | 14.30M | 10.56M | 8.03M | 5.65M | 1.78M | 548.77K |
| Interest Income | 505.00K | 1.27M | 0.00 | 53.00K | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 589.00K | 1.27M | 0.00 | 53.00K | 32.67K | 2.39M | 724.68K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.93M | 2.55M | 226.00K | 23.00K | 14.23K | 9.79K | 7.11K | 3.79K | 1.78M | 422.29K |
| EBITDA | -75.74M | -99.41M | -55.90M | -35.81M | -16.67M | -12.07M | -11.15M | -5.65M | -1.78M | -126.48K |
| EBITDA Ratio | -3,088.99% | -24,615.92% | -10,833.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -68.80M | -90.93M | -54.39M | -23.35M | -14.30M | -10.56M | -8.03M | -5.65M | -1.78M | -422.29K |
| Operating Income Ratio | -2,805.67% | -24,118.57% | -10,878.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.47M | -12.15M | -1.73M | -12.54M | -2.97M | -7.61M | -1.49M | 0.00 | 0.00 | -126.48K |
| Income Before Tax | -79.26M | -103.24M | -56.13M | -35.89M | -17.27M | -18.17M | -9.52M | -5.65M | -1.78M | -548.77K |
| Income Before Tax Ratio | -3,232.59% | -27,384.08% | -11,225.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -1.94M | -5.78M | -1.56M | -1.34M | -204.07K | 878.87K | -1.00 | -1.78M | -126.48K |
| Net Income | -64.18M | -101.29M | -50.35M | -34.33M | -15.93M | -17.97M | -9.52M | -5.65M | -1.78M | -548.77K |
| Net Income Ratio | -2,617.25% | -26,868.44% | -10,069.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| EPS Diluted | -9.16 | -15.03 | -9.80 | -10.93 | -8.31 | -12.63 | -11.56 | -6.53 | -2.36 | -0.96 |
| Weighted Avg Shares Out | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
| Weighted Avg Shares Out (Dil) | 7.23M | 5.94M | 5.17M | 3.16M | 2.01M | 1.49M | 899.73K | 864.81K | 751.92K | 574.55K |
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
PAVmed Announces Dividend of Lucid Diagnostics Common Stock and Reverse Stock Split
PAVmed Inc. (PAVM) Q3 2023 Earnings Call Transcript
PAVmed Provides Business Update and Third Quarter Financial Results
Lucid Diagnostics Provides Business Update and Third Quarter Financial Results
Lucid Diagnostics Launches Next-Generation EsoGuard® Esophageal DNA Test and Announces Upcoming Investor Day
PAVmed to Hold a Business Update Conference Call and Webcast on November 15, 2023
Here's Why PAVmed Inc. (PAVM) Is a Great 'Buy the Bottom' Stock Now
Lucid Diagnostics Executes First Direct Employer Contract to Provide EsoGuard® Esophageal Precancer Testing as an Employee Benefit
PAVmed Inc. (PAVM) Upgraded to Buy: Here's Why
Source: https://incomestatements.info
Category: Stock Reports